Placebo News and Research

RSS

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.

5 May 2010

Medication used to treat heart arrhythmias also reduces myotonic dystrophy: Researchers

A medication most often used to treat heart arrhythmias also reduces a central symptom of myotonic dystrophy, the most common type of muscular dystrophy in adults.

5 May 2010

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.

5 May 2010

Australian researchers show positive effect of growth hormone on athletic performance

Australian researchers have published the results of a study, for the first time showing a positive effect of growth hormone on athletic performance.

5 May 2010

Vitamin A does not improve maternal, infant health, study finds

Giving women vitamin A supplements does not reduce maternal death rates or improve the health of infants, according to a study published Tuesday in the Lancet, the New York Times reports.

5 May 2010

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute during Digestive Disease Week 2010 in New Orleans, Louisiana.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.

5 May 2010

Clinical development of RG7128 is on track: Pharmasset

Pharmasset, Inc., in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today that the development of RG7128 is on track, and that no safety or other concerns have delayed the program.

4 May 2010

Vanda reports total revenue of $12.4 million for first-quarter 2010

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2010.

4 May 2010

HGH improves athletic performance: Study

A study released today in Annals of Internal Medicine, the flagship journal of the American College of Physicians, finds that human growth hormone improves sprint capacity in healthy recreational athletes. This is the first trial to demonstrate that HGH improves athletic performance.

4 May 2010

Research makes progress in ending guesswork involved in prescribing effective ADHD medications

Children with ADHD who carry a specific type of dopamine receptor gene respond better to the drug methylphenidate than those without the genotype, according to new research from Cincinnati Children's Hospital Medical Center.

4 May 2010

Algal DHA improves memory function in healthy aging adults: MIDAS

The Memory Improvement with Docosahexaenoic acid Study published online this week in Alzheimer's & Dementia: The Journal of the Alzheimer's Association showed that algal DHA improved memory function in healthy aging adults, providing a benefit roughly equivalent to having the learning and memory skills of someone three years younger.

4 May 2010

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.

4 May 2010

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Sucampo Pharmaceuticals, Inc. today presented results of a phase 2 clinical trial of cobiprostone, an investigational drug, for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). These data were presented at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, as part of the distinguished abstract plenary session.

4 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

Growth hormone boosts sprinting capacity in athletes but may have serious side effects

Human Growth Hormone (hGH) has long been used among athletes and body builders for stronger and a more muscular bodies over the past four decades. However it is only now that Sydney-based researchers have published a study that shows that hGH offers no such benefits.

3 May 2010

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.

3 May 2010

Protein test to determine response of lung cancer patients to erlotinib

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

3 May 2010

New classification of depressive subtypes of depression proposed

Lichtenberg and Belmaker propose a new classification of depressive subtypes of depression in the current issue of Psychotherapy and Psychosomatics. They argue that a simple diagnosis is no longer sufficient to guide treatment.

3 May 2010

Placebo News and Research

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Medication used to treat heart arrhythmias also reduces myotonic dystrophy: Researchers

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

Australian researchers show positive effect of growth hormone on athletic performance

Vitamin A does not improve maternal, infant health, study finds

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Clinical development of RG7128 is on track: Pharmasset

Vanda reports total revenue of $12.4 million for first-quarter 2010

HGH improves athletic performance: Study

Research makes progress in ending guesswork involved in prescribing effective ADHD medications

Algal DHA improves memory function in healthy aging adults: MIDAS

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Growth hormone boosts sprinting capacity in athletes but may have serious side effects

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Protein test to determine response of lung cancer patients to erlotinib

New classification of depressive subtypes of depression proposed

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News